Sarcomas as a mise en abyme of mesenchymal stem cells: Exploiting interrelationships for cell mediated anticancer therapy

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 1-10

  Burns, Jorge S ^a   Safwat, Akmal ^b,c   Grisendi, Giulia ^a   Kassem, Moustapha ^c,d   Dominici, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cell therapy; Mesenchymal stem cell; Radiation; Sarcoma; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CEDIRANIB; CHEMOKINE RECEPTOR CXCR4; CRIZOTINIB; CYTOSINE DEAMINASE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; FLUCYTOSINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; REXIN G; RNA BINDING PROTEIN EWS; SOMATOMEDIC C RECEPTOR ANTIBODY; TELOMERASE; TRABECTEDIN; TRANSCRIPTION FACTOR FLI 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANGIOGENESIS; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CELL FUSION; CELL HOMING; CELL SECRETION; CHEMOSENSITIVITY; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION X; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ENTOSIS; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; IMMUNOMODULATION; LUNG METASTASIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SHORT SURVEY;

EID: 84865306057     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.027     Document Type: Review

References (152)

1. Bianco P., Robey P.G., Saggio I., Riminucci M. "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Human Gene Ther. 2010, 21:1057-1066.
2. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Human Gene Ther. 2010, 21:1045-1056.
3. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
4. Mafi P., Hindocha S., Mafi R., Griffin M., Khan W.S. Adult mesenchymal stem cells and cell surface characterization - a systematic review of the literature. Open Orthop. J. 2011, 5:253-260.
5. Aranda P., Agirre X., Ballestar E., Andreu E.J., Roman-Gomez J., Prieto I., Martin-Subero J.I., Cigudosa J.C., Siebert R., Esteller M., Prosper F. Epigenetic signatures associated with different levels of differentiation potential in human stem cells. PLoS One 2009, 4:e7809.
6. Choi M.Y., Kim H.I., Yang Y.I., Kim J.T., Jang S.H., Park C.M., Jang W.H., Youn Y.C., Cheong S.H., Choi C.S., Kim D.K., Lee S.J. The isolation and in situ identification of MSCs residing in loose connective tissues using a niche-preserving organ culture system. Biomaterials 2012, 33:4469-4479.
7. Rodriguez R., Rubio R., Gutierrez-Aranda I., Melen G.J., Elosua C., Garcia-Castro J., Menendez P. FUS-CHOP fusion protein expression coupled to p53 deficiency induces liposarcoma in mouse but not in human adipose-derived mesenchymal stem/stromal cells. Stem Cells 2011, 29:179-192.
8. Jeong J.O., Han J.W., Kim J.M., Cho H.J., Park C., Lee N., Kim D.W., Yoon Y.S. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ. Res. 2011, 108:1340-1347.
9. Torsvik A., Rosland G.V., Svendsen A., Molven A., Immervoll H., McCormack E., Lonning P.E., Primon M., Sobala E., Tonn J.C., Goldbrunner R., Schichor C., Mysliwietz J., Lah T.T., Motaln H., Knappskog S., Bjerkvig R. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010, 70:6393-6396.
10. Poloni A., Maurizi G., Babini L., Serrani F., Berardinelli E., Mancini S., Costantini B., Discepoli G., Leoni P. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant. 2011, 20:643-654.
11. Prockop D.J., Brenner M., Fibbe W.E., Horwitz E., Le Blanc K., Phinney D.G., Simmons P.J., Sensebe L., Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010, 12:576-578.
12. Berger M., Muraro M., Fagioli F., Ferrari S. Osteosarcoma derived from donor stem cells carrying the Norrie's disease gene. New Engl. J. Med. 2008, 359:2502-2504.
13. Perrot P., Rousseau J., Bouffaut A.L., Redini F., Cassagnau E., Deschaseaux F., Heymann M.F., Heymann D., Duteille F., Trichet V., Gouin F. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One 2010, 5:e10999.
14. Sensebe L., Bourin P., Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Human Gene Ther. 2011, 22:19-26.
15. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., Fazioli F., Pirozzi G., Papaccio G. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J. 2011, 25:2022-2030.
16. Mohseny A.B., Hogendoorn P.C. Concise review: mesenchymal tumors: when stem cells go mad. Stem cells 2011, 29:397-403.
17. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
18. Brune J.C., Tormin A., Johansson M.C., Rissler P., Brosjo O., Lofvenberg R., von Steyern F.V., Mertens F., Rydholm A., Scheding S. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Int. J. Cancer 2011, 129:319-330.
19. Suva M.L., Riggi N., Stehle J.C., Baumer K., Tercier S., Joseph J.M., Suva D., Clement V., Provero P., Cironi L., Osterheld M.C., Guillou L., Stamenkovic I. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009, 69:1776-1781.
20. Riggi N., Suva M.L., De Vito C., Provero P., Stehle J.C., Baumer K., Cironi L., Janiszewska M., Petricevic T., Suva D., Tercier S., Joseph J.M., Guillou L., Stamenkovic I. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010, 24:916-932.
21. Fujii H., Honoki K., Tsujiuchi T., Kido A., Yoshitani K., Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol. 2009, 34:1381-1386.
22. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 2008, 8:545-554.
23. Singh S., Kloss F.R., Brunauer R., Schimke M., Jamnig A., Greiderer-Kleinlercher B., Klima G., Rentenberger J., Auberger T., Hachl O., Rasse M., Gassner R., Lepperdinger G. Mesenchymal stem cells show radioresistance in vivo. J. Cell Mol. Med. 2012, 16:877-887.
24. D'Andrea F.P., Safwat A., Kassem M., Gautier L., Overgaard J., Horsman M.R. Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiother. Oncol. 2011, 99:373-378.
25. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
26. Serakinci N., Guldberg P., Burns J.S., Abdallah B., Schrodder H., Jensen T., Kassem M. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004, 23:5095-5098.
27. Burns J.S., Abdallah B.M., Guldberg P., Rygaard J., Schroder H.D., Kassem M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res. 2005, 65:3126-3135.
28. Burns J.S., Abdallah B.M., Schroder H.D., Kassem M. The histopathology of a human mesenchymal stem cell experimental tumor model: support for an hMSC origin for Ewing's sarcoma?. Histol. Histopathol. 2008, 23:1229-1240.
29. Balamuth N.J., Womer R.B. Ewing's sarcoma. Lancet Oncol. 2010, 11:184-192.
30. Pinto A., Dickman P., Parham D. Pathobiologic markers of the Ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma 2011, 2011:856190.
31. Takahashi A., Higashino F., Aoyagi M., Yoshida K., Itoh M., Kyo S., Ohno T., Taira T., Ariga H., Nakajima K., Hatta M., Kobayashi M., Sano H., Kohgo T., Shindoh M. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res. 2003, 63:8338-8344.
32. Li X., McGee-Lawrence M.E., Decker M., Westendorf J.J. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation. J. Cell. Biochem. 2010, 111:933-943.
33. von Levetzow C., Jiang X., Gwye Y., von Levetzow G., Hung L., Cooper A., Hsu J.H., Lawlor E.R. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One 2011, 6:e19305.
34. Bielack S.S., Paulussen M., Kohler G. A patient with two Ewing's sarcomas with distinct EWS fusion transcripts. New Engl. J. Med. 2004, 350:1364-1365.
35. Garcia C.B., Shaffer C.M., Alfaro M.P., Smith A.L., Sun J., Zhao Z., Young P.P., Vansaun M.N., Eid J.E. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. Oncogene 2011, 2323-2334.
36. Naka N., Takenaka S., Araki N., Miwa T., Hashimoto N., Yoshioka K., Joyama S., Hamada K., Tsukamoto Y., Tomita Y., Ueda T., Yoshikawa H., Itoh K. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010, 28:1119-1131.
37. Yamaoka E., Hiyama E., Sotomaru Y., Onitake Y., Fukuba I., Sudo T., Sueda T., Hiyama K. Neoplastic transformation by TERT in FGF-2-expanded human mesenchymal stem cells. Int. J. Oncol. 2011, 39:5-11.
38. Mitelman F., Johansson B., Mertens F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007, 7:233-245.
39. Rodriguez R., Rubio R., Menendez P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res. 2012, 22:62-77.
40. Song C., Li G. CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy 2011, 13:549-561.
41. Reagan M.R., Kaplan D.L. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 2011, 29:920-927.
42. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., Battula V.L., Weil M., Andreeff M., Marini F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
43. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., Semprun-Prieto L., Delafontaine P., Prockop D.J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
44. Albarenque S.M., Zwacka R.M., Mohr A. Both human and mouse mesenchymal stem cells promote breast cancer metastasis. Stem Cell Res. 2011, 7:163-171.
45. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F.r. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29:11-19.
46. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., Nguyen A.T., Malide D., Combs C.A., Hall G., Zhang J., Raffeld M., Rogers T.B., Stetler-Stevenson W., Frank J.A., Reitz M., Finkel T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 2006, 203:1235-1247.
47. Gibellini D., Alviano F., Miserocchi A., Tazzari P.L., Ricci F., Clo A., Morini S., Borderi M., Viale P., Pasquinelli G., Pagliaro P., Bagnara G.P., Re M.C. HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells. Retrovirology 2011, 8:40.
48. Sorrell J.M., Caplan A.I. Topical delivery of mesenchymal stem cells and their function in wounds. Stem Cell Res. Ther. 2010, 1:30.
49. Suzuki K., Sun R., Origuchi M., Kanehira M., Takahata T., Itoh J., Umezawa A., Kijima H., Fukuda S., Saijo Y. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol. Med. 2011, 17:579-587.
50. Yu L., Su B., Hollomon M., Deng Y., Facchinetti V., Kleinerman E.S. Vasculogenesis driven by bone marrow-derived cells is essential for growth of Ewing's sarcomas. Cancer Res. 2010, 70:1334-1343.
51. Fang S., Salven P. Stem cells in tumor angiogenesis. J. Mol. Cell. Cardiol. 2011, 50:290-295.
52. Feng J., Mantesso A., De Bari C., Nishiyama A., Sharpe P.T. Dual origin of mesenchymal stem cells contributing to organ growth and repair. Proc. Natl. Acad. Sci. USA 2011, 108:6503-6508.
53. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., Tagliafico E., Ferrari S., Robey P.G., Riminucci M., Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
54. Nagy J.A., Chang S.H., Dvorak A.M., Dvorak H.F. Why are tumour blood vessels abnormal and why is it important to know?. Br. J. Cancer 2009, 100:865-869.
55. Fan W., Crawford R., Xiao Y. The ratio of VEGF/PEDF expression in bone marrow mesenchymal stem cells regulates neovascularization. Differentiation 2011, 81:181-191.
56. Burns J.S., Kristiansen M., Kristensen L.P., Larsen K.H., Nielsen M.O., Christiansen H., Nehlin J., Andersen J.S., Kassem M. Decellularized matrix from tumorigenic human mesenchymal stem cells promotes neovascularization with galectin-1 dependent endothelial interaction. PLoS One 2011, 6:e21888.
57. Paunescu V., Bojin F.M., Tatu C.A., Gavriliuc O.I., Rosca A., Gruia A.T., Tanasie G., Bunu C., Crisnic D., Gherghiceanu M., Tatu F.R., Tatu C.S., Vermesan S. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J. Cell Mol. Med. 2011, 15:635-646.
58. Roorda B.D., ter Elst A., Kamps W.A., de Bont E.S. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit. Rev. Oncol. Hematol. 2009, 69:187-198.
59. Bian Z.Y., Li G., Gan Y.K., Hao Y.Q., Xu W.T., Tang T.T. Increased number of mesenchymal stem cell-like cells in peripheral blood of patients with bone sarcomas. Arch. Med. Res. 2009, 40:163-168.
60. Morozov A., Downey R.J., Healey J., Moreira A.L., Lou E., Franceschino A., Dogan Y., Leung R., Edgar M., LaQuaglia M., Maki R.G., Moore M.A. Benign mesenchymal stromal cells in human sarcomas. Clin. Cancer Res. 2010, 16:5630-5640.
61. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci. 2010, 101:2554-2560.
62. Avital I., Moreira A.L., Klimstra D.S., Leversha M., Papadopoulos E.B., Brennan M., Downey R.J. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007, 25:2903-2909.
63. Mathivanan S., Ji H., Simpson R.J. Exosomes: extracellular organelles important in intercellular communication. J. Proteomics 2010, 73:1907-1920.
64. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El Oakley R.M., Pasterkamp G., de Kleijn D.P., Lim S.K. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010, 4:214-222.
65. Gatti S., Bruno S., Deregibus M.C., Sordi A., Cantaluppi V., Tetta C., Camussi G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 2011, 26:1474-1483.
66. Cho J.A., Park H., Lim E.H., Lee K.W. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int. J. Oncol. 2012, 40:130-138.
67. Chen T.S., Lai R.C., Lee M.M., Choo A.B., Lee C.N., Lim S.K. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010, 38:215-224.
68. Lulla R.R., Costa F.F., Bischof J.M., Chou P.M., Bonaldo M. de F., Vanin E.F., Soares M.B. Identification of differentially expressed MicroRNAs in osteosarcoma. Sarcoma 2011, 732690.
69. Dela Cruz F., Matushansky I. MicroRNAs in chromosomal translocation-associated solid tumors: learning from sarcomas. Discovery. Med. 2011, 12:307-317.
70. Del Tatto M., Ng T., Aliotta J.M., Colvin G.A., Dooner M.S., Berz D., Dooner G.J., Papa E.F., Hixson D.C., Ramratnam B., Aswad B.I., Sears E.H., Reagan J., Quesenberry P.J. Marrow cell genetic phenotype change induced by human lung cancer cells. Exp. Hematol. 2011, 39:1072-1080.
71. Gao P., Zheng J. Oncogenic virus-mediated cell fusion: new insights into initiation and progression of oncogenic viruses-related cancers. Cancer Lett. 2011, 303:1-8.
72. Taylor B.S., Barretina J., Maki R.G., Antonescu C.R., Singer S., Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat. Rev. Cancer 2011, 11:541-557.
73. Krajcovic M., Johnson N.B., Sun Q., Normand G., Hoover N., Yao E., Richardson A.L., King R.W., Cibas E.S., Schnitt S.J., Brugge J.S., Overholtzer M. A non-genetic route to aneuploidy in human cancers. Nat. Cell Biol. 2011, 13:324-330.
74. Overholtzer M., Brugge J.S. The cell biology of cell-in-cell structures. Nat. Rev. Mol. Cell Biol. 2008, 9:796-809.
75. Frable W.J., Bonfiglio T.A., Kaminsky D.B., Murphy W.M. Diagnostic cytology seminar. Acta Cytol. 1980, 24:90-136.
76. K.C. Chao, H.T. Yang, M.W. Chen, Human umbilical cord mesenchymal stem cells suppress breast cancer tumorigenesis through direct cell-cell contact and internalization, J. Cell Mol. Med., in press. (Epub ahead of print). doi:10.1111/j.1582-4934.2011.01459.x.
77. Pawelek J.M., Chakraborty A.K. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat. Rev. Cancer 2008, 8:377-386.
78. Ferrand J., Noel D., Lehours P., Prochazkova-Carlotti M., Chambonnier L., Menard A., Megraud F., Varon C. Human bone marrow-derived stem cells acquire epithelial characteristics through fusion with gastrointestinal epithelial cells. PLoS One 2011, 6:e19569.
79. English K., French A., Wood K.J. Mesenchymal stromal cells: facilitators of successful transplantation?. Cell Stem Cell 2010, 7:431-442.
80. Nasef A., Ashammakhi N., Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen. Med. 2008, 3:531-546.
81. Gieseke F., Bohringer J., Bussolari R., Dominici M., Handgretinger R., Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779.
82. Sioud M., Mobergslien A., Boudabous A., Floisand Y. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int. J. Oncol. 2011, 38:385-390.
83. Ringden O., Le Blanc K. Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract. Res. Clin. Haematol. 2011, 24:65-72.
84. Yaguchi T., Sumimoto H., Kudo-Saito C., Tsukamoto N., Ueda R., Iwata-Kajihara T., Nishio H., Kawamura N., Kawakami Y. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 2011, 93:294-300.
85. Johann P.D., Vaegler M., Gieseke F., Mang P., Armeanu-Ebinger S., Kluba T., Handgretinger R., Muller I. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer 2010, 10:501.
86. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., Ebert B.L., Al-Shahrour F., Hasserjian R.P., Scadden E.O., Aung Z., Matza M., Merkenschlager M., Lin C., Rommens J.M., Scadden D.T. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
87. Houghton J., Li H., Fan X., Liu Y., Liu J.H., Rao V.P., Poutahidis T., Taylor C.L., Jackson E.A., Hewes C., Lyle S., Cerny A., Bowen G., Cerny J., Moore N., Kurt-Jones E.A., Erdman S.E. Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev. 2010, 19:1153-1166.
88. Xiang J., Tang J., Song C., Yang Z., Hirst D.G., Zheng Q.J., Li G. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 2009, 11:516-526.
89. Dwyer R.M., Kerin M.J. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?. Human Gene Ther. 2010, 21:1506-1512.
90. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv. Drug Delivery Rev. 2012, 64:739-748.
91. Grisendi G., Bussolari R., Veronesi E., Piccinno S., Burns J.S., De Santis G., Loschi P., Pignatti M., Di Benedetto F., Ballarin R., Di Gregorio C., Guarneri V., Piccinini L., Horwitz E.M., Paolucci P., Conte P., Dominici M. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Am. J. Cancer Res. 2011, 1:787-805.
92. Mohr A., Lyons M., Deedigan L., Harte T., Shaw G., Howard L., Barry F., O'Brien T., Zwacka R. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J. Cell Mol. Med. 2008, 12:2628-2643.
93. Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Oh J.H., Jeong M., Oh W., Park S.H., Sung Y.C., Jeun S.S. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 2008, 68:9614-9623.
94. Subbiah V., Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr. Opin. Oncol. 2011, 23:352-360.
95. Subbiah V., Anderson P. Targeted therapy of Ewing's sarcoma. Sarcoma 2011, 2011:686985.
96. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., Novotny W., Goldwasser M.A., Tohnya T.M., Lum B.L., Ashkenazi A., Jubb A.M., Mendelson D.S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2846.
97. Cihova M., Altanerova V., Altaner C. Stem cell based cancer gene therapy. Mol. Pharm. 2011, 8:1480-1487.
98. Yang B., Wu X., Mao Y., Bao W., Gao L., Zhou P., Xie R., Zhou L., Zhu J. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 2009, 65:610-624.
99. Picarda G., Trichet V., Teletchea S., Heymann D., Redini F. TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am. J. Cancer Res. 2012, 2:45-64.
100. Wang S., Ren W., Liu J., Lahat G., Torres K., Lopez G., Lazar A.J., Hayes-Jordan A., Liu K., Bankson J., Hazle J.D., Lev D. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 2010, 16:2591-2604.
101. Szegezdi E., O'Reilly A., Davy Y., Vawda R., Taylor D.L., Murphy M., Samali A., Mehmet H. Stem cells are resistant to TRAIL receptor-mediated apoptosis. J. Cell Mol. Med. 2009, 13:4409-4414.
102. Kim S.M., Oh J.H., Park S.A., Ryu C.H., Lim J.Y., Kim D.S., Chang J.W., Oh W.I., Jeun S.S. Irradiation enhances the tumor tropism and therapeutic potential of TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem cells 2010, 28:2217-2228.
103. O.M. Niemoeller, C. Belka, Radiotherapy and TRAIL for cancer therapy, Cancer Lett., in press. (Epub ahead of print). doi:10.1016/j.canlet.2011.07.003.
104. Coppes R.P., van der Goot A., Lombaert I.M. Stem cell therapy to reduce radiation-induced normal tissue damage. Semin. Radiat. Oncol. 2009, 19:112-121.
105. Greenberger J.S., Epperly M. Bone marrow-derived stem cells and radiation response. Semin. Radiat. Oncol. 2009, 19:133-139.
106. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009, 69:4134-4142.
107. Loebinger M.R., Sage E.K., Davies D., Janes S.M. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br. J. Cancer 2010, 103:1692-1697.
108. Nagy K., Szekely-Szuts K., Izeradjene K., Douglas L., Tillman M., Barti-Juhasz H., Dominici M., Spano C., Luca Cervo G., Conte P., Houghton J.A., Mihalik R., Kopper L., Petak I. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Pathol. Oncol. Res. 2006, 12:133-142.
109. Mohr A., Albarenque S.M., Deedigan L., Yu R., Reidy M., Fulda S., Zwacka R.M. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 2010, 28:2109-2120.
110. Bagci-Onder T., Wakimoto H., Anderegg M., Cameron C., Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011, 71:154-163.
111. Moon M.H., Jeong J.K., Seo J.S., Seol J.W., Lee Y.J., Xue M., Jackson C.J., Park S.Y. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp. Mol. Med. 2011, 43:138-145.
112. Liu Y., Han Z.P., Zhang S.S., Jing Y.Y., Bu X.X., Wang C.Y., Sun K., Jiang G.C., Zhao X., Li R., Gao L., Zhao Q.D., Wu M.C., Wei L.X. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J. Biol. Chem. 2011, 286:25007-25015.
113. Grisendi G., Bussolari R., Cafarelli L., Petak I., Rasini V., Veronesi E., De Santis G., Spano C., Tagliazzucchi M., Barti-Juhasz H., Scarabelli L., Bambi F., Frassoldati A., Rossi G., Casali C., Morandi U., Horwitz E.M., Paolucci P., Conte P., Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010, 70:3718-3729.
114. Barti-Juhasz H., Mihalik R., Nagy K., Grisendi G., Dominici M., Petak I. Bone marrow derived mesenchymal stem/stromal cells transduced with full length human TRAIL repress the growth of rhabdomyosarcoma cells in vitro. Haematologica 2011, 96:e21-2.
115. Mohseny A.B., Machado I., Cai Y., Schaefer K.L., Serra M., Hogendoorn P.C., Llombart-Bosch A., Cleton-Jansen A.M. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 2011, 91:1195-1205.
116. Mohseny A.B., Tieken C., van der Velden P.A., Szuhai K., de Andrea C., Hogendoorn P.C., Cleton-Jansen A.M. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosom. Cancer 2010, 49:1095-1103.
117. Gjerstorff M., Burns J.S., Nielsen O., Kassem M., Ditzel H. Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy. Am. J. Pathol. 2009, 175:314-323.
118. Vishnubalaji R., Al-Nbaheen M., Kadalmani B., Aldahmash A., Ramesh T. Comparative investigation of the differentiation capability of bone-marrow- and adipose-derived mesenchymal stem cells by qualitative and quantitative analysis. Cell Tissue Res. 2012, 347:419-427.
119. J.G. Shi, W.J. Fu, X.X. Wang, Y.D. Xu, G. Li, B.F. Hong, K. Hu, F.Z. Cui, Y. Wang, X. Zhang, Transdifferentiation of human adipose-derived stem cells into urothelial cells: potential for urinary tract tissue engineering, Cell Tissue Res., in press. (Epub ahead of print). doi:10.1007/s00441-011-1317-0.
120. Yu G., Floyd Z.E., Wu X., Hebert T., Halvorsen Y.D., Buehrer B.M., Gimble J.M. Adipogenic differentiation of adipose-derived stem cells. Methods Mol. Biol. 2011, 702:193-200.
121. Nakagami H., Morishita R., Maeda K., Kikuchi Y., Ogihara T., Kaneda Y. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J Atheroscler. Thromb. 2006, 13:77-81.
122. Winter A., Breit S., Parsch D., Benz K., Steck E., Hauner H., Weber R.M., Ewerbeck V., Richter W. Cartilage-like gene expression in differentiated human stem cell spheroids: a comparison of bone marrow-derived and adipose tissue-derived stromal cells. Arthritis Rheum. 2003, 48:418-429.
123. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P., Hedrick M.H. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001, 7:211-228.
124. De Coppi P., Bartsch G.J., Siddiqui M.M., Xu T., Santos C.C., Perin L., Mostoslavsky G., Serre A.C., Snyder E.Y., Yoo J.J., Furth M.E., Soker S., Atala A. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 2007, 25:100-106.
125. Tsai M.S., Lee J.L., Chang Y.J., Hwang S.M. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Human Reprod. 2004, 19:1450-1456.
126. Sohni A., Verfaillie C.M. Multipotent adult progenitor cells. Best Pract. Res. Clin. Haematol. 2011, 24:3-11.
127. Santourlidis S., Wernet P., Ghanjati F., Graffmann N., Springer J., Kriegs C., Zhao X., Brands J., Arauzo-Bravo M.J., Neves R., Koegler G., Uhrberg M. Unrestricted somatic stem cells (USSC) from human umbilical cord blood display uncommitted epigenetic signatures of the major stem cell pluripotency genes. Stem Cell Res. 2011, 6:60-69.
128. Sauerzweig S., Munsch T., Lessmann V., Reymann K.G., Braun H. A population of serum deprivation-induced bone marrow stem cells (SD-BMSC) expresses marker typical for embryonic and neural stem cells. Exp. Cell Res. 2009, 315:50-66.
129. Beltrami A.P., Cesselli D., Bergamin N., Marcon P., Rigo S., Puppato E., D'Aurizio F., Verardo R., Piazza S., Pignatelli A., Poz A., Baccarani U., Damiani D., Fanin R., Mariuzzi L., Finato N., Masolini P., Burelli S., Belluzzi O., Schneider C., Beltrami C.A. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood 2007, 110:3438-3446.
130. Kucia M., Halasa M., Wysoczynski M., Baskiewicz-Masiuk M., Moldenhawer S., Zuba-Surma E., Czajka R., Wojakowski W., Machalinski B., Ratajczak M.Z. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 2007, 21:297-303.
131. D'Ippolito G., Diabira S., Howard G.A., Menei P., Roos B.A., Schiller P.C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J. Cell Sci. 2004, 117:2971-2981.
132. Gronthos S., Chen S., Wang C.Y., Robey P.G., Shi S. Telomerase accelerates osteogenesis of bone marrow stromal stem cells by upregulation of CBFA1, osterix, and osteocalcin. J. Bone Miner. Res. 2003, 18:716-722.
133. Kuznetsov S.A., Mankani M.H., Robey P.G. Effect of serum on human bone marrow stromal cells: ex vivo expansion and in vivo bone formation. Transplantation 2000, 70:1780-1787.
134. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9:641-650.
135. Klein D., Weisshardt P., Kleff V., Jastrow H., Jakob H.G., Ergun S. Vascular wall-resident CD44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation. PLoS One 2011, 6:e20540.
136. A. Leszczynska, A. O'Doherty, F. Barry, T. O'Brien, M. Murphy, 8 Ossification of atherosclerotic plaque: the role of vessel derived stem cells, Heart 97, in press. (Epub ahead of print). doi:10.1136/heartjnl-2011-300920b.8.
137. V. Paracchini, A. Carbone, F. Colombo, S. Castellani, S. Mazzucchelli, S.D. Gioia, D. Degiorgio, M. Seia, L. Porretti, C. Colombo, M. Conese, Amniotic mesenchymal stem cells: a new source for hepatocyte-like cells and induction of CFTR expression by coculture with cystic fibrosis airway epithelial cells, J Biomed. Biotechnol., in press. (Epub ahead of print). doi:10.1155/2012/575471.
138. Ratajczak M.Z., Zuba-Surma E.K., Machalinski B., Ratajczak J., Kucia M. Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev. 2008, 4:89-99.
139. Kogler G., Sensken S., Airey J.A., Trapp T., Muschen M., Feldhahn N., Liedtke S., Sorg R.V., Fischer J., Rosenbaum C., Greschat S., Knipper A., Bender J., Degistirici O., Gao J., Caplan A.I., Colletti E.J., Almeida-Porada G., Muller H.W., Zanjani E., Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 2004, 200:123-135.
140. Rosada C., Justesen J., Melsvik D., Ebbesen P., Kassem M. The human umbilical cord blood: a potential source for osteoblast progenitor cells. Calcif. Tissue Int. 2003, 72:135-142.
141. Iwata T., Yamato M., Zhang Z., Mukobata S., Washio K., Ando T., Feijen J., Okano T., Ishikawa I. Validation of human periodontal ligament-derived cells as a reliable source for cytotherapeutic use. J. Clin. Periodontol. 2010, 37:1088-1099.
142. Miura M., Gronthos S., Zhao M., Lu B., Fisher L.W., Robey P.G., Shi S. SHED: stem cells from human exfoliated deciduous teeth. Proc. Natl. Acad. Sci. USA 2003, 100:5807-5812.
143. Gronthos S., Mankani M., Brahim J., Robey P.G., Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2000, 97:13625-13630.
144. Spitzer T.L., Rojas A., Zelenko Z., Aghajanova L., Erikson D.W., Barragan F., Meyer M., Tamaresis J.S., Hamilton A.E., Irwin J.C., Giudice L.C. Perivascular human endometrial mesenchymal stem cells express pathways relevant to self-renewal, lineage specification, and functional phenotype. Biol. Reprod. 2012, 86. 58, 1-16.
145. Murphy M.P., Wang H., Patel A.N., Kambhampati S., Angle N., Chan K., Marleau A.M., Pyszniak A., Carrier E., Ichim T.E., Riordan N.H. Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia?. J. Transl. Med. 2008, 6:45.
146. Hida N., Nishiyama N., Miyoshi S., Kira S., Segawa K., Uyama T., Mori T., Miyado K., Ikegami Y., Cui C., Kiyono T., Kyo S., Shimizu T., Okano T., Sakamoto M., Ogawa S., Umezawa A. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008, 26:1695-1704.
147. Delorme B., Nivet E., Gaillard J., Haupl T., Ringe J., Deveze A., Magnan J., Sohier J., Khrestchatisky M., Roman F.S., Charbord P., Sensebe L., Layrolle P., Feron F. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev. 2010, 19:853-866.
148. Jakob M., Hemeda H., Janeschik S., Bootz F., Rotter N., Lang S., Brandau S. Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. Stem Cells Dev. 2010, 19:635-644.
149. Kassis I., Zangi L., Rivkin R., Levdansky L., Samuel S., Marx G., Gorodetsky R. Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant. 2006, 37:967-976.
150. Zvaifler N.J., Marinova-Mutafchieva L., Adams G., Edwards C.J., Moss J., Burger J.A., Maini R.N. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000, 2:477-488.
151. Igura K., Zhang X., Takahashi K., Mitsuru A., Yamaguchi S., Takashi T.A. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy 2004, 6:543-553.
152. Salvolini E., Orciani M., Vignini A., Mattioli-Belmonte M., Mazzanti L., Di Primio R. Skin-derived mesenchymal stem cells (S-MSCs) induce endothelial cell activation by paracrine mechanisms. Exp. Dermatol. 2010, 19:848-850.